Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol + ropivacaine
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Intravenous, Epidural
01
Overview
A combination of the general anesthetic propofol and the local anesthetic ropivacaine. Propofol is a sedative-hypnotic agent that acts through positive modulation of GABA-A receptors, while ropivacaine is a local anesthetic that blocks sodium channels to prevent nerve impulse generation and conduction. This combination is commonly used in surgical settings where both general anesthesia and regional pain control are desired, offering benefits such as reduced propofol requirements, better hemodynamic stability, and improved postoperative pain control.
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on propofol + ropivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol + ropivacaine.